Sept 20: The FDA surprised ARS Pharmaceuticalsif the tone of the companys press release is any indicationby issuing a Complete Response Letter for neffy, an epinephrine nasal spray, in type 1 allergic reactions, including anaphylaxis
Mol Cell Biol, 2003
Baseline metabolic health matters, plain and simple
Los nuevos medicamentos, como los agonistas del GLP-1 , Semaglutida y Tirzepatida, no solo facilitan una reduccin significativa del peso mediante la imitacin de las hormonas naturales de la saciedad sino que tambin contribuyen a mejorar los perfiles metablicos y a mantener los resultados a largo plazo
In Phase 3 trials, 1218% of participants discontinued due to side effects (vs
3 Cardiac arrhythmias affected 2-11% of participants on retatrutide versus 2% on placebo, but none were serious